Artelo Biosciences, Inc. (ARTL)
NASDAQ: ARTL · Real-Time Price · USD
1.910
-0.205 (-9.69%)
At close: Nov 6, 2026, 4:00 PM EST
1.930
+0.020 (1.05%)
After-hours: Nov 6, 2026, 7:30 PM EST
Artelo Biosciences Employees
Artelo Biosciences had 7 employees as of December 31, 2025. The number of employees increased by 1 or 16.67% compared to the previous year. That makes Artelo Biosciences the 40,925th largest employer in the world and 6,244th in the United States.
Employees
7
Change (1Y)
1
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$1,810,143
Market Cap
1.05M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7 | 1 | 16.67% |
| Jun 30, 2025 | 5 | 0 | - |
| Mar 31, 2025 | 5 | 0 | - |
| Dec 31, 2024 | 6 | 0 | - |
| Sep 30, 2024 | 5 | 0 | - |
| Jun 30, 2024 | 5 | 0 | - |
| Mar 31, 2024 | 5 | 0 | - |
| Dec 31, 2023 | 6 | -1 | -14.29% |
| Sep 30, 2023 | 5 | 1 | 25.00% |
| Jun 30, 2023 | 5 | 1 | 25.00% |
| Mar 31, 2023 | 5 | 1 | 25.00% |
| Dec 31, 2022 | 7 | 2 | 40.00% |
| Sep 30, 2022 | 4 | -1 | -20.00% |
| Jun 30, 2022 | 4 | - | - |
| Mar 31, 2022 | 4 | - | - |
| Dec 31, 2021 | 5 | 2 | 66.67% |
| Nov 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Feb 29, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Feb 28, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 228 |
| PMGC Holdings | 34 |
| GeoVax Labs | 19 |
| Silexion Therapeutics | 14 |
| Decoy Therapeutics | 11 |
| Oragenics | 3 |
| Propanc Biopharma | 2 |
| Bone Biologics | 2 |
ARTL News
- 10 days ago - Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on Pain - GlobeNewsWire
- 13 days ago - Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain - GlobeNewsWire
- 4 weeks ago - Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform - GlobeNewsWire
- 6 weeks ago - Why Is Penny Stock Artelo Biosciences (ARTL) Up Over 200% Today? - TipRanks
- 6 weeks ago - Artelo Biosciences files new provisional patent application covering ART27.13 - TheFly
- 6 weeks ago - Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings - GlobeNewsWire
- 7 weeks ago - Artelo Biosciences announces results from nonclinical study of ART27.13 - TheFly
- 7 weeks ago - Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity - GlobeNewsWire